TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8647061

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (WHF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Soy collagen hydrolysate formula (SCHF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Whey-casein hydrolysate formula (WCHF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Whey predominant hydrolysed preterm formulas
Number of subjects: 80

Group type: COMPARATOR
Intervention: All three protein hydrolysate formulas
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Some hydrolysate formulas
Number of subjects: 80
Study: 2113036

Group type: EXPERIMENTAL
Intervention: Balanced amino acid solution (Study group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard Rose's formula (Control group)
Number of subjects: 18
Study: 468450

Group type: EXPERIMENTAL
Intervention: High lipid meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: High protein meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: High carbohydrate meal
Number of subjects: 6
Study: 28277430

Group type: EXPERIMENTAL
Intervention: Interrepetition rest design
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cluster design
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traditional design
Number of subjects: 17
Study: 28421677

Group type: EXPERIMENTAL
Intervention: MBSR (8 weekly group sessions of MBSR)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Active controls (self-instructing MBSR)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Non-MBSR
Number of subjects: 166
Study: 25944411

Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg administered intravenously) plus diet counselling
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Single dose of zoledronate (5 mg administered intravenously) plus diet counselling
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (diet counselling only)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Two doses of zoledronate (5 mg administered intravenously) plus diet counselling
Number of subjects: 31
Study: 23351627

Group type: EXPERIMENTAL
Intervention: Single-serving label format
Number of subjects: 9493

Group type: EXPERIMENTAL
Intervention: Dual-column label format
Number of subjects: 9493

Group type: COMPARATOR
Intervention: Single column label format with 2 servings
Number of subjects: 9493
Study: 21317630

Group type: EXPERIMENTAL
Intervention: Clinician-delivered quitline intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control standard brief stop-smoking intervention
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Quitline intervention
Number of subjects: 300
Study: 18218053

Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Gold alloy frameworks
Number of subjects: 52
Study: 16484504

Group type: EXPERIMENTAL
Intervention: High trough concentration (10‐15 ng/ml) group (HT group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 63
Study: 12920610

Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid for 15 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid for 15 s and 5% sodium hypochlorite for 2 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite for 5 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 0
Study: 10740552

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 50
Study: 8633831

Group type: EXPERIMENTAL
Intervention: Once-daily aminoglycoside dosing
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard aminoglycoside regimens
Number of subjects: 13
Study: 1421050

Group type: EXPERIMENTAL
Intervention: Tegretol 200 mg commercial tablets
Number of subjects: 34

Group type: COMPARATOR
Intervention: carbamazepine OROS controlled delivery tablets
Number of subjects: 34
Study: 3882676

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 0
Study: 31557810

Group type: EXPERIMENTAL
Intervention: Facility List Coder (FLC)
Number of subjects: 301
Study: 29704217

Group type: EXPERIMENTAL
Intervention: Smoking as usual (n=50)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Overnight abstinence (n=50 successfully abstained, n=22 failed abstaining)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 128
Study: 27510380

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV//Hib pentavalent combination vaccine (Pentaxim™)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Separate DTaP‐IPV and Hib vaccines
Number of subjects: 418
Study: 25061038

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD) treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo SWD treatment
Number of subjects: 31
Study: 24114748

Group type: EXPERIMENTAL
Intervention: Free rehabilitation (n = 32): 2 weeks of ROM 0°-90°, no brace, touch weightbearing, unrestricted activity and free ROM thereafter.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Restricted rehabilitation (n = 28): 6 weeks of hinged brace use, gradual increase of ROM to 90°, only touch weightbearing during the 6 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with repair failure who underwent subsequent partial meniscectomy.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall outcomes for both groups (free and restricted rehabilitation).
Number of subjects: 60
Study: 22121446

Group type: EXPERIMENTAL
Intervention: Health education intervention in Kake II (experimental arm)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group in Barombi-Kang
Number of subjects: 370
Study: 19451282

Group type: EXPERIMENTAL
Intervention: EDP-420 (400 mg/day loading dose, followed by 200 mg/day for 2 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EDP-420 capsule formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: EDP-420 suspension formulation
Number of subjects: 0
Study: 16505262

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (700 IU) plus Calcium Citrate Malate (500 mg)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study: 14630381

Group type: EXPERIMENTAL
Intervention: Discussing patient's ideas about their disorder
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Discussing patient's action plans
Number of subjects: 108

Group type: COMPARATOR
Intervention: Care-as-usual consultation
Number of subjects: 108
Study: 10676679

Group type: EXPERIMENTAL
Intervention: PC180 (180 s ischemia)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: NC (80 microg/kg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: PC60 (60 s ischemia)
Number of subjects: 46

Group type: COMPARATOR
Intervention: ISDN (40 microg/kg)
Number of subjects: 46
Study: 9039852

Group type: EXPERIMENTAL
Intervention: Dairy-containing diet
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nondairy-containing diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Baseline diet
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Second days in laboratory
Number of subjects: 25
Study: 8000747

Group type: EXPERIMENTAL
Intervention: Verum acupuncture treatment at non-segmental distal points (homolateral leg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo acupuncture (avoiding penetration of the skin)
Number of subjects: 48
Study: 3287976

Group type: EXPERIMENTAL
Intervention: Cefotetan 2 g once daily
Number of subjects: 194

Group type: COMPARATOR
Intervention: Cefoxitin 1 or 2 g three times daily
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 194

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 194
Study: 30030775

Group type: EXPERIMENTAL
Intervention: Low Intensity Aerobic Exercise with Blood Flow Restriction (LIAE + BFR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High Intensity Aerobic Exercise (HIAE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low Intensity Aerobic Exercise (LIAE)
Number of subjects: 16
Study: 28028866

Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK) performed in groups during working hours for 5 × 10 minutes per week and up to five group‐based coaching sessions on motivation for regular physical exercise
Number of subjects: 200

Group type: COMPARATOR
Intervention: Home‐based physical exercise (HOME) performed alone during leisure‐time for 5 × 10 minutes per week
Number of subjects: 200
Study: 26233970

Group type: EXPERIMENTAL
Intervention: Marginal Periosteal Membrane (MPM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Marginal Periosteal Membrane (MPM) with Demineralized Freeze-Dried Bone Allograft (DFDBA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 30
Study: 24453079

Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 mg 3 times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 22915294

Group type: EXPERIMENTAL
Intervention: Cowpea meal fortified with 10 mg Fe/meal as NaFeEDTA
Number of subjects: 241

Group type: COMPARATOR
Intervention: Nonfortified cowpea meal
Number of subjects: 241
Study: 20420745

Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy patients
Number of subjects: 23
Study: 19115654

Group type: COMPARATOR
Intervention: Lignocaine alone (9 ml of 2% lignocaine diluted with normal saline to total volume of 36 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lignocaine plus magnesium sulphate (6 ml of 25% magnesium sulphate plus 9 ml of 2% lignocaine diluted with normal saline to total volume of 36 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lignocaine plus magnesium sulphate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lignocaine alone
Number of subjects: 30
Study: 16235974

Group type: EXPERIMENTAL
Intervention: Orlistat plus diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 0
Study: 12084443

Group type: EXPERIMENTAL
Intervention: Peripheral silent period in ET patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Peripheral silent period in healthy controls
Number of subjects: 24
Study: 11482123

Group type: EXPERIMENTAL
Intervention: Preventive services benefit package
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 9169299

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 405
Study: 8330606

Group type: EXPERIMENTAL
Intervention: Forearm elevation to 0 cm above heart
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Forearm elevation to 18 cm above heart
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Forearm elevation to 36 cm above heart
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Forearm blood flow at heart level
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total vascular resistance at heart level
Number of subjects: 20
Study: 3943744

Group type: EXPERIMENTAL
Intervention: Hyoscine‐N‐butylbromide (20 mg IV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyoscine‐N‐butylbromide (40 mg IV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study: 31393811

Group type: EXPERIMENTAL
Intervention: Mastery Motivational Climate (MMC) intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 96
Study: 30188253

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser combined with an exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham laser combined with an exercise program
Number of subjects: 60
Study: 27671996

Group type: EXPERIMENTAL
Intervention: Swiss ball
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dumbbells
Number of subjects: 36

Group type: COMPARATOR
Intervention: Smith machine
Number of subjects: 36
Study: 24767296

Group type: EXPERIMENTAL
Intervention: Short-term thromboprophylaxis with oral rivaroxaban 10 mg once daily for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long-term thromboprophylaxis with oral rivaroxaban 10 mg once daily for 35 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (short-term thromboprophylaxis)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (long-term thromboprophylaxis)
Number of subjects: 40
Study: 23248894

Group type: EXPERIMENTAL
Intervention: Novel multi-directional power toothbrush (Oral-B Professional Deep Sweep TRICLEAN 1000)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard soft manual control toothbrush
Number of subjects: 119
Study: 20975473

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 321
Study: 19192854

Group type: EXPERIMENTAL
Intervention: Abstinence-contingent monetary payments for 14 days with 0, 1, or 8 experimenter-delivered cigarette puffs
Number of subjects: 58

Group type: COMPARATOR
Intervention: Abstinence-contingent monetary payments for 1 day
Number of subjects: 58
Study: 16014402

Group type: EXPERIMENTAL
Intervention: High-protein/low-fat diet (34% protein/29% fat)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard protein/high-fat diet (18% protein/45% fat)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High-protein/low-fat diet
Number of subjects: 57
Study: 11978683

Group type: EXPERIMENTAL
Intervention: NVP DPP728 at 100 mg t.i.d.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: NVP DPP728 at 150 mg b.i.d.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: NVP DPP728 (combined active treatment groups)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: NVP DPP728 at 100 mg t.i.d. and 150 mg b.i.d.
Number of subjects: 93
Study: 10599480

Group type: EXPERIMENTAL
Intervention: Children at high risk for anxiety disorders
Number of subjects: 192

Group type: COMPARATOR
Intervention: Other children
Number of subjects: 192
Study: 7568603

Group type: EXPERIMENTAL
Intervention: Structured statement of exercise intention after three 90-min educational sessions
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no structured statement of intention)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Structured statements of intention
Number of subjects: 111
Study: 8095941

Group type: EXPERIMENTAL
Intervention: Allergic subjects after allergen challenge (Parietaria judaica)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy individuals after allergen challenge (Parietaria judaica)
Number of subjects: 30
Study: 2871819

Group type: EXPERIMENTAL
Intervention: Diazepam (4.4 to 140 micrograms/kg, cumulative dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30043330

Group type: EXPERIMENTAL
Intervention: G‐CSF + plerixafor (GP arm)
Number of subjects: 32

Group type: COMPARATOR
Intervention: G‐CSF alone (G arm)
Number of subjects: 32
Study: 27764050

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (10 obese patients with schizophrenia)
Number of subjects: 22
Study: 24632673

Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C (rh-APC) 24 mcg/kg/h for 4 days
Number of subjects: 71

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C (rh-APC)
Number of subjects: 71
Study: 22572649

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg in 20 mL 0.9% saline)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (20 mL 0.9% saline)
Number of subjects: 32
Study: 20090428

Group type: COMPARATOR
Intervention: Placebo or sham-controlled intervention
Number of subjects: 0
Study: 18612039

Group type: EXPERIMENTAL
Intervention: Frequent cell phone interviews (Parent-Child Activities Interview)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Less frequent interviews over home telephone
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Parent-Child Activities Interview
Number of subjects: 589
Study: 16006230

Group type: EXPERIMENTAL
Intervention: Caregiver correlates including demographics, behaviors, family environment, perceptions of parent/adolescent interaction, coping strategies, caregiver monitoring of youth, and self-reported substance use.
Number of subjects: 218
Study: 12089229

Group type: EXPERIMENTAL
Intervention: ChlVPP/EVA hybrid
Number of subjects: 282

Group type: COMPARATOR
Intervention: VAPEC-B
Number of subjects: 282
Study: 10557684

Group type: EXPERIMENTAL
Intervention: Interactive group education and peer review programme (four sessions each lasting two hours)
Number of subjects: 433

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 433
Study: 8540714

Group type: EXPERIMENTAL
Intervention: Ceftazidime 25 mg/kg once daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ceftazidime 25 mg/kg twice daily
Number of subjects: 28
Study: 1786500

Group type: EXPERIMENTAL
Intervention: Pramiracetam sulphate 400 mg TID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6821435

Group type: EXPERIMENTAL
Intervention: Staged, intact canal wall tympanoplasties
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staged, modified radical mastoidectomies with cavity obliteration and tympanoplasty
Number of subjects: 0
Study: 31343513

Group type: EXPERIMENTAL
Intervention: MiSight 1-day contact lens (test)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Proclear 1-day (control)
Number of subjects: 144
Study: 28489244

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 22
Study: 26201187

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (medical treatment)
Number of subjects: 112
Study: 24180582

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study: 22140666

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap surgery combined with CO2 laser root conditioning (CAF + CO2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Modified Widman flap surgery (MW)
Number of subjects: 25
Study: 19508900

Group type: EXPERIMENTAL
Intervention: Celecoxib (specific dosage and duration not mentioned)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Radio advertisements
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Internet postings
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Print media
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Posted and racked flyers
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mass mailings
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Other strategies (referrals)
Number of subjects: 137
Study: 17348993

Group type: EXPERIMENTAL
Intervention: Avène thermal spring water (ATSW)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparative water spray
Number of subjects: 25
Study: 15586841

Group type: EXPERIMENTAL
Intervention: Feeling Thermometer with marker states (FT+)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Feeling Thermometer without marker states (FT-)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Standard Gamble with marker states (SG+)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Standard Gamble without marker states (SG-)
Number of subjects: 217
Study: 11505514

Group type: EXPERIMENTAL
Intervention: Fixed insole (lateral wedged insole with elastic fixation of the subtalar joint)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Inserted insole (traditional shoe insert wedged insoles)
Number of subjects: 71
Study: 9543954

Group type: EXPERIMENTAL
Intervention: Motivational video and peer counseling intervention
Number of subjects: 242
Study: 7843473

Group type: EXPERIMENTAL
Intervention: Bespoke shoes (cushioned shoes prescribed up to 2 pairs on request)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normal shoes (control group)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Bespoke shoes (cases)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normal shoes (controls)
Number of subjects: 85
Study: 2450441

Group type: EXPERIMENTAL
Intervention: Atracurium 0.1 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancuronium 0.6 mg kg‐1
Number of subjects: 60
Study: 29694816

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (approximately 20 mg per kilogram of body weight)
Number of subjects: 190238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190238

Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 190238
Study: 29326491

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 25179766

Group type: EXPERIMENTAL
Intervention: Home Monitoring facilitated follow-up (HM ON)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Regular in-office follow-up (HM OFF)
Number of subjects: 312
Study: 23299396

Group type: COMPARATOR
Intervention: Response Signals (RS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deadlines (DL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance-contingent payment (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flat payment (Experiment 2)
Number of subjects: 0
Study: 20686919

Group type: EXPERIMENTAL
Intervention: Laser pulse length of 0.604mS (group I)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Laser pulse length of 0.708mS (group II)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Laser pulse length of 1.010mS (group III)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Comparison of all groups (I, II, III)
Number of subjects: 240
Study: 18706905

Group type: EXPERIMENTAL
Intervention: 100 microg/day transdermal estradiol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 34
Study: 16624680

Group type: EXPERIMENTAL
Intervention: Metoprolol XL
Number of subjects: 13

Group type: COMPARATOR
Intervention: Metoprolol IR
Number of subjects: 13
Study: 14615000

Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study: 10762502

Group type: EXPERIMENTAL
Intervention: Patients with RLS and PLMs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 10